首頁 > 市場調查報告書 > 製藥

市場調查報告書

商品編碼

1561030

肝素市場規模、佔有率、成長分析、按類型、按給藥途徑、按原料、按應用、按最終用戶、按地區 - 行業預測，2024-2031 年

Heparin Market Size, Share, Growth Analysis, By Type, By Route of Administration,, By Source, By Application, By End User, By Region - Industry Forecast 2024-2031

出版日期: 2024年09月19日 | 出版商:

SkyQuest | 英文 219 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

2022年全球肝素市場規模為73.2億美元，從2023年的75.1億美元成長到2031年的92.2億美元，預測期間（2024-2031年）複合年成長率為2.6%，預計將成長至2022年。

2022 年 8 月，FDA核准了Momenta 學名藥是與諾華公司學名藥部門 Sandoz 合作開發的 Robenox 學名藥。由於技術的改進，M-依諾肝素主要用於大型整形外科手術，例如置換術和膝關節關節重建。肝素研究的最新趨勢，特別是開發用於化療的超低分子量肝素的努力，為肝素市場創造了新的成長機會。肝素廣泛用於治療多種疾病，包括深層靜脈栓塞症、肺動脈栓塞、急性冠狀動脈症候群、心房顫動和心血管手術期間的血液濾過。其應用在整形外科和心血管手術中極為重要，例如髖關節和關節重建。心血管疾病引起的靜脈血栓症的發生率不斷增加，推動了全球肝素市場的擴張。此外，肝素在心血管手術和整形外科手術等各種外科手術中的使用不斷增加，進一步推動了市場成長。然而，一些挑戰限制了市場的擴張，包括肝素引起的血小板減少症等副作用。此外，由於它依賴動物源性肝素，因此存在安全性和可得性的擔憂，這是一個限制。

市場概況
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲國家地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 其他亞太地區
拉丁美洲
- 巴西
- 其他拉丁美洲地區
中東和非洲 (MEA)
- 海灣合作理事會國家
- 南非
- 其他中東/非洲地區

競爭格局

前5名企業對比
主要企業市場定位（2023年）
主要市場參與者所採取的策略
近期市集活動
主要企業市場佔有率（2023年）

主要企業簡介

Pfizer Inc.（US）
LEO Pharma A/S（Denmark）
Dr. Reddy's Laboratories Ltd.（India）
Sanofi（France）
Aspen Holdings（South Africa）
Fresenius SE & Co. KGaA（Germany）
B. Braun Medical, Inc.（US）
Sandoz（Novartis AG）（Switzerland）
Teva Pharmaceutical Industries Ltd.（Israel）
Hikma Pharmaceuticals PLC（UK）
Amphastar Pharmaceuticals, Inc.（US）
Baxter International Inc.（US）
Shanghai Fosun Pharmaceutical（Group）Co., Ltd.（China）
Bioiberica SAU（Spain）
CSL Limited（Australia）
Laboratorios ROVI SA（Spain）
Opocrin SpA（Italy）
Shandong Dongcheng Biochemicals Co., Ltd.（China）
Techdow Pharmaceutical Co., Ltd.（China）
Syntex SA（Argentina）
Jiangxi Haike Biotechnology Co., Ltd.（China）
Chemi SpA（Italy）
Changzhou Qianhong Bio-pharma Co., Ltd.（China）
Hebei Changshan Biochemical Pharmaceutical Co., Ltd.（China）
Hebei Yipin Pharmaceutical Co., Ltd.（China）
King-friend Biochemical Pharmaceutical Co., Ltd.（China）
Yantai Dongcheng Biochemicals Co., Ltd.（China）
Nanjing Jianyou Biochemical Pharmaceutical Co., Ltd.（China）

簡介目錄

Product Code: SQMIG35H2166

Global Heparin Market size was valued at USD 7.32 billion in 2022 and is poised to grow from USD 7.51 billion in 2023 to USD 9.22 billion by 2031, growing at a CAGR of 2.6% during the forecast period (2024-2031).

In August 2022, the FDA approved Momenta Pharmaceuticals, Inc.'s M-Enoxaparin, a generic version of Lovenox developed in collaboration with Sandoz, Novartis AG's generics division. M-Enoxaparin, enhanced with improved technology, is primarily used in major orthopedic procedures such as hip and knee replacements. Recent advances in heparin research, particularly efforts to develop ultra-low molecular weight heparin for chemotherapy, have opened new growth opportunities in the heparin market. Heparin is widely used to treat various conditions including deep vein thrombosis, pulmonary embolism, acute coronary syndrome, atrial fibrillation, and hemofiltration during heart surgery. Its application is crucial in orthopedic surgeries, such as hip and knee replacements, as well as in cardiovascular procedures. The growing incidence of venous thrombosis, driven by cardiovascular diseases, is fueling the expansion of the global heparin market. Additionally, the increasing use of heparin in various surgical operations, including heart and orthopedic surgeries, further drives market growth. However, several challenges limit the market's expansion, including adverse side effects such as heparin-induced thrombocytopenia. Another constraint is the reliance on animal-derived heparin, which raises concerns regarding safety and availability.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Heparin market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Heparin Market Segmental Analysis

Global Heparin Market is segmented by Type, Route of Administration, Application, end user and region. Based on Type, the market is segmented into Low Molecular Weight Heparin, Ultra-low Molecular Weight Heparin, Unfractionated Heparin. Based on Route of Administration, the market is segmented into Intravenous, Subcutaneous. Based on Source, the market is segmented into Porcine, Bovine, Others. Based on Application, the market is segmented into Venous Thromboembolism, Atrial Fibrillation, Renal Impairment, Coronary Artery Disease, Others. Based on end user, the market is segmented into Outpatient, Inpatient. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Drivers of the Global Heparin Market

The demand for heparin is rising as coagulation disorders like venous thromboembolism (VTE), which includes deep vein thrombosis and pulmonary embolism, become more prevalent. VTE is responsible for over 1.2 million deaths annually and is the leading cause of death in Europe, surpassing AIDS, breast and prostate cancer, and traffic accidents combined. Additionally, the global heparin market is expanding due to the increasing incidence of hypertension, often linked to unhealthy lifestyles. The growing rates of heart attacks and strokes present new business opportunities for the heparin industry. According to the American Heart Association (AHA), atrial fibrillation affects 5.3 million Americans, further contributing to the rising demand for heparin. As more patients require treatment for these conditions, the market for heparin is expected to see significant growth.

Restraints in the Global Heparin Market

One of the main challenges hindering the expansion of the heparin market is its adverse side effects. The most common complication associated with heparin use is bleeding, which can occur spontaneously in areas such as the lips, gums, ovaries, uterus, intestines, stomach, and open surgical wounds. Additionally, heparin can trigger a serious condition known as heparin-induced thrombocytopenia (HIT), in which the immune system creates antibodies against the body's platelets, increasing the risk of bleeding. These potential side effects may slow market growth during the forecast period as concerns about safety persist.

Market Trends of the Global Heparin Market

As the use of heparin and other anticoagulant therapies rises, there is an increasing demand for effective reversal agents to mitigate their anticoagulant effects, particularly in emergency situations or during surgical procedures. The need for these agents is critical to ensure patient safety and manage complications that may arise from excessive bleeding. Ongoing research and development efforts are focused on creating new anticoagulant reversal agents, offering an additional growth opportunity for the heparin market. These advancements could enhance the safety profile of anticoagulant therapies and further drive market expansion by addressing a key medical need.

Introduction

Objectives of the Study
Definitions
Market Scope

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Market Overview Outlook
Supply Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Technology Analysis
Pricing Analysis
Value Chain Analysis
Ecosystem of the Market
Trade Analysis
Supply chain Analysis
Case study Analysis
Patent Analysis
Customer & Buying Criteria Analysis
Regulatory Landscape
Innovation Matrix
Top Investment Analysis
Key Success Factor
Degree of Competition

Heparin Market by Type

Market Overview
Low Molecular Weight Heparin
Ultra-low Molecular Weight Heparin
Unfractionated Heparin

Heparin Market by Route of Administration

Market Overview
Intravenous
Subcutaneous

Heparin Market by Source

Market Overview
Porcine
Bovine
Others

Heparin Market by Application

Market Overview
Venous Thromboembolism
Atrial Fibrillation
Renal Impairment
Coronary Artery Disease
Others

Heparin Market by End-use

Market Overview
Outpatient
Inpatient

Heparin Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2023
Strategies Adopted by Key Market Players
Recent Activities in the Market
Key Companies Market Share (%), 2023

Key Company Profiles

Pfizer Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
LEO Pharma A/S (Denmark)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Dr. Reddy's Laboratories Ltd. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Aspen Holdings (South Africa)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Fresenius SE & Co. KGaA (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
B. Braun Medical, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sandoz (Novartis AG) (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teva Pharmaceutical Industries Ltd. (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Hikma Pharmaceuticals PLC (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Amphastar Pharmaceuticals, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Baxter International Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bioiberica S.A.U. (Spain)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
CSL Limited (Australia)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Laboratorios ROVI S.A. (Spain)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Opocrin S.p.A. (Italy)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Shandong Dongcheng Biochemicals Co., Ltd. (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Techdow Pharmaceutical Co., Ltd. (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Syntex S.A. (Argentina)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Jiangxi Haike Biotechnology Co., Ltd. (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Chemi S.p.A. (Italy)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Changzhou Qianhong Bio-pharma Co., Ltd. (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Hebei Changshan Biochemical Pharmaceutical Co., Ltd. (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Hebei Yipin Pharmaceutical Co., Ltd. (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
King-friend Biochemical Pharmaceutical Co., Ltd. (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Yantai Dongcheng Biochemicals Co., Ltd. (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Nanjing Jianyou Biochemical Pharmaceutical Co., Ltd. (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments